AU2020396647A1 - Method for producing peptide having physiological activity, and peptide comprising short linker - Google Patents

Method for producing peptide having physiological activity, and peptide comprising short linker Download PDF

Info

Publication number
AU2020396647A1
AU2020396647A1 AU2020396647A AU2020396647A AU2020396647A1 AU 2020396647 A1 AU2020396647 A1 AU 2020396647A1 AU 2020396647 A AU2020396647 A AU 2020396647A AU 2020396647 A AU2020396647 A AU 2020396647A AU 2020396647 A1 AU2020396647 A1 AU 2020396647A1
Authority
AU
Australia
Prior art keywords
peptide
amino acid
pas
aet
physiologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020396647A
Other languages
English (en)
Inventor
Ayako FUJIWARA
Kenichiro Ito
Michiya KANZAKI
Yoshimi Kikuchi
Atsushi Konishi
Yoshihiko Matsuda
Kyohei MIYAIRI
Kazutoshi Takahashi
Naoko Yamada
Hiroki Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of AU2020396647A1 publication Critical patent/AU2020396647A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2020396647A 2019-12-06 2020-12-04 Method for producing peptide having physiological activity, and peptide comprising short linker Pending AU2020396647A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-221040 2019-12-06
JP2019221040 2019-12-06
PCT/JP2020/045327 WO2021112249A1 (ja) 2019-12-06 2020-12-04 生理活性を有するペプチドの製造方法及び短鎖リンカーを含むペプチド

Publications (1)

Publication Number Publication Date
AU2020396647A1 true AU2020396647A1 (en) 2022-07-07

Family

ID=76221763

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020396647A Pending AU2020396647A1 (en) 2019-12-06 2020-12-04 Method for producing peptide having physiological activity, and peptide comprising short linker

Country Status (7)

Country Link
US (1) US20220396819A1 (https=)
EP (1) EP4071178A4 (https=)
JP (2) JPWO2021112249A1 (https=)
KR (1) KR20220110556A (https=)
CN (1) CN114787198A (https=)
AU (1) AU2020396647A1 (https=)
WO (1) WO2021112249A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240032941A (ko) 2021-07-07 2024-03-12 아지노모토 가부시키가이샤 비천연 아미노산 함유 단백질의 분비 생산법
JPWO2023200008A1 (https=) 2022-04-15 2023-10-19
WO2023234416A1 (ja) 2022-06-02 2023-12-07 味の素株式会社 親和性物質、化合物、抗体およびそれらの塩
EP4324843A1 (en) * 2022-08-18 2024-02-21 SenseUp GmbH Production of crm197
CN117024601A (zh) * 2023-07-14 2023-11-10 合肥工业大学 一种宣威火腿源抗氧化肽及其制备方法和活性测定方法
TW202602903A (zh) * 2024-03-18 2026-01-16 日商肽夢想股份有限公司 肽、肽複合物、醫藥組成物、細胞培養用組成物以及用於醫療用、診斷用或研究用的組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US6083913A (en) * 1995-06-07 2000-07-04 Glaxo Wellcome Inc. Peptides and compounds that bind to a thrombopoietin receptor
JP4035855B2 (ja) 1996-06-05 2008-01-23 味の素株式会社 Ｌ−リジンの製造法
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
EP1986677A2 (en) * 2006-01-25 2008-11-05 Amgen Inc. Thrombopoietic compounds
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
JP2010083808A (ja) * 2008-09-30 2010-04-15 Institute Of Physical & Chemical Research 新規ペプチド誘導体を含む造血系細胞増殖促進剤
US9221882B2 (en) * 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
JP2014534265A (ja) * 2011-11-28 2014-12-18 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド インスリンアミノ酸配列を含む治療薬
CN104684546A (zh) * 2012-06-07 2015-06-03 哈佛大学校长及研究员协会 用于药物靶向的纳米疗法
US9994616B2 (en) * 2013-10-15 2018-06-12 The University Of Tokyo c-Met protein agonist
DK3287523T3 (da) 2015-04-24 2022-07-25 Ajinomoto Kk Fremgangsmåde til sekretorisk fremstilling af protein
US11459397B2 (en) * 2016-01-08 2022-10-04 Meditope Biosciences Inc. Self-crosslinking antibodies
CN110891612A (zh) * 2017-06-21 2020-03-17 Xl-蛋白有限责任公司 蛋白质药物与p/a肽的缀合物

Also Published As

Publication number Publication date
JPWO2021112249A1 (https=) 2021-06-10
WO2021112249A1 (ja) 2021-06-10
EP4071178A4 (en) 2024-10-09
EP4071178A1 (en) 2022-10-12
US20220396819A1 (en) 2022-12-15
JP2025113367A (ja) 2025-08-01
KR20220110556A (ko) 2022-08-08
CN114787198A (zh) 2022-07-22

Similar Documents

Publication Publication Date Title
AU2020396647A1 (en) Method for producing peptide having physiological activity, and peptide comprising short linker
EP1991560B1 (en) Peptide having cell membrane penetrating activity
Hofmann et al. Recent advances in the application of expressed protein ligation to protein engineering
JP4972191B2 (ja) ペプチド、蛋白質及びペプチドミメティック合成のための方法及び組成物
JP2011231085A (ja) 環状ペプチド
KR20100044128A (ko) 바이포달 펩타이드 바인더
WO2003091429A1 (en) Antimicrobial polypeptide and utizliation thereof
US20010055783A1 (en) Recombinant phycobiliprotein and phycobiliprotein linker fusion proteins and uses therefore
TW201309720A (zh) 胜肽庫
KR20240042497A (ko) 폴리펩타이드의 제작 방법, 태그, 발현 벡터, 폴리펩타이드의 평가 방법, 핵산 디스플레이 라이브러리의 제작 방법 및 스크리닝 방법
US20250270610A1 (en) Improving the Efficiency of PAL-Catalyzed Protein Ligation By A Cascade Enzymatic Scheme
US11865181B2 (en) Peptidic materials that traffic efficiently to the cell cytosol and nucleus
JP5865002B2 (ja) 組換えプラスミドベクターおよびそれを用いたタンパク質の製造方法
CN112608366B (zh) 超正电荷聚多肽及其制备方法、应用
EP2575846A1 (en) Insulin-like growth factor 1 receptor binding peptides
US20240026343A1 (en) Method for screening dimerized cyclic peptide
US20220073908A1 (en) Methods of producing high diversity peptide libraries and promoting protein folding
Beutel et al. Bind&Bite: Covalently stabilized heterodimeric coiled-coil peptides for the site-selective, cysteine-free chemical modification of proteins
CN108440671B (zh) 一种来源于foxm1蛋白的抗肿瘤多肽
WO2015115661A1 (ja) アゾール誘導体骨格を有するペプチドの製造方法
KR20210097547A (ko) 생체 물질 전달용 세포 투과성 펩타이드
KR101784455B1 (ko) Ｃ형 간염 바이러스의 친수성 단편을 포함하는 융합 폴리펩티드, 그를 포함하는 c형 간염 바이러스 감염을 진단하기 위한 조성물, 키트, 및 방법
CN109415425A (zh) TGF-β超家族的AB6家族设计配体
Kakizawa et al. Fmoc‐based solid phase chemical synthesis of 71‐meric neuregulin 1‐β1, an epidermal growth factor‐like domain
HK40097236A (zh) 半胱氨酸结蛋白的制造方法